Sergei Agoulnik

1.3k total citations
16 papers, 898 citations indexed

About

Sergei Agoulnik is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sergei Agoulnik has authored 16 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Sergei Agoulnik's work include Cancer Treatment and Pharmacology (4 papers), MicroRNA in disease regulation (3 papers) and Cancer-related Molecular Pathways (3 papers). Sergei Agoulnik is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), MicroRNA in disease regulation (3 papers) and Cancer-related Molecular Pathways (3 papers). Sergei Agoulnik collaborates with scholars based in United States, Japan and Switzerland. Sergei Agoulnik's co-authors include Yoshiya Oda, Zoltán Dezső, Yasuhiro Funahashi, Mamoru Yanagimachi, Pavan Kumar, Judy Oestreicher, Ken Aoshima, Crystal MacKenzie, François P. Bernier and Michael Byrne and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Sergei Agoulnik

15 papers receiving 880 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergei Agoulnik United States 9 438 348 332 147 75 16 898
Evelyn Aranda United States 11 412 0.9× 210 0.6× 126 0.4× 55 0.4× 41 0.5× 12 753
Houjie Liang China 19 459 1.0× 238 0.7× 215 0.6× 69 0.5× 83 1.1× 36 862
Daya Luo China 15 513 1.2× 225 0.6× 318 1.0× 112 0.8× 37 0.5× 48 907
Zarir E. Karanjawala United States 14 708 1.6× 330 0.9× 222 0.7× 127 0.9× 108 1.4× 23 1.1k
Keigo Araki Japan 13 767 1.8× 373 1.1× 504 1.5× 44 0.3× 58 0.8× 24 1.1k
Sandeep Singh United States 15 642 1.5× 424 1.2× 255 0.8× 94 0.6× 34 0.5× 25 972
Rajan Gogna United States 19 546 1.2× 266 0.8× 318 1.0× 60 0.4× 48 0.6× 36 919
Melanie Spitzner Germany 19 880 2.0× 377 1.1× 208 0.6× 124 0.8× 30 0.4× 30 1.2k
Robert S. Banh United States 6 529 1.2× 435 1.3× 288 0.9× 133 0.9× 37 0.5× 8 1.2k
Hannie Sietsma Netherlands 19 751 1.7× 282 0.8× 109 0.3× 172 1.2× 86 1.1× 22 1.0k

Countries citing papers authored by Sergei Agoulnik

Since Specialization
Citations

This map shows the geographic impact of Sergei Agoulnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergei Agoulnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergei Agoulnik more than expected).

Fields of papers citing papers by Sergei Agoulnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergei Agoulnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergei Agoulnik. The network helps show where Sergei Agoulnik may publish in the future.

Co-authorship network of co-authors of Sergei Agoulnik

This figure shows the co-authorship network connecting the top 25 collaborators of Sergei Agoulnik. A scholar is included among the top collaborators of Sergei Agoulnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergei Agoulnik. Sergei Agoulnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Torres, Lidiane S., Lucas Fernando Sérgio Gushiken, Flávia C. Leonardo, et al.. (2024). Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition. Haematologica. 110(3). 725–738. 1 indexed citations
2.
Huang, Kuan‐Chun, Zhihong Chen, Yimin Jiang, et al.. (2016). Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61. Molecular Cancer Therapeutics. 15(6). 1208–1216. 55 indexed citations
3.
Matsuki, Masahiro, Kiyoshi Okamoto, Zoltán Dezső, et al.. (2016). Abstract 3266: Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines. Cancer Research. 76(14_Supplement). 3266–3266.
4.
McGonigle, Sharon, Jiayi Wu, Donna Kolber‐Simonds, et al.. (2015). Abstract P5-06-03: Combination of the PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of triple negative breast cancer. Cancer Research. 75(9_Supplement). P5–6. 1 indexed citations
5.
Dezső, Zoltán, Judith Oestreicher, Stephanie Santiago, et al.. (2014). Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells. PLoS ONE. 9(8). e106131–e106131. 50 indexed citations
6.
Yoshida, Takeshi, Yoichi Ozawa, Takayuki Kimura, et al.. (2014). Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states. British Journal of Cancer. 110(6). 1497–1505. 284 indexed citations
7.
Agoulnik, Sergei, Satoshi Kawano, Noël Taylor, et al.. (2014). Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. PubMed. 6(1). 3–3. 33 indexed citations
8.
Agoulnik, Sergei, Judith Oestreicher, Noël Taylor, et al.. (2013). Abstract 3830: Eribulin and Paclitaxel differentially affect gene expression profiling of blood vessel cells and in vitro angiogenesis in co-cultures of human endothelial cells with pericytes.. Cancer Research. 73(8_Supplement). 3830–3830. 2 indexed citations
9.
Kumar, Pavan, Zoltán Dezső, Crystal MacKenzie, et al.. (2013). Circulating miRNA Biomarkers for Alzheimer's Disease. PLoS ONE. 8(7). e69807–e69807. 306 indexed citations
10.
Kumar, Pavan, Zoltán Dezső, Crystal MacKenzie, et al.. (2013). P1–234: Circulating miRNA biomarkers for Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_6). 1 indexed citations
11.
Dezső, Zoltán, Judith Oestreicher, Tadashi Kadowaki, et al.. (2013). Abstract 1522: Gene expression profiling (GEP) reveals Epithelial Mesenchymal Transition (EMT) genes selectively differentiating eribulin sensitive breast cancer cell lines.. Cancer Research. 73(8_Supplement). 1522–1522. 1 indexed citations
12.
O’Shannessy, Daniel J., Stephen M. Jackson, Natalie C. Twine, et al.. (2013). Gene Expression Analyses Support Fallopian Tube Epithelium as the Cell of Origin of Epithelial Ovarian Cancer. International Journal of Molecular Sciences. 14(7). 13687–13703. 23 indexed citations
13.
Bono, Johann S. de, L. Rhoda Molife, Guru Sonpavde, et al.. (2011). Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Annals of Oncology. 23(5). 1241–1249. 44 indexed citations
14.
Kuznetsov, Galina, Qunli Xu, Karen TenDyke, et al.. (2009). Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Molecular Cancer Therapeutics. 8(5). 1250–1260. 85 indexed citations
15.
Wu, Jiayi, K. Nomoto, John Wang, et al.. (2009). Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts. Cancer Research. 69. 3687–3687. 3 indexed citations
16.
Agoulnik, Sergei, Galina Kuznetsov, Karen TenDyke, et al.. (2005). Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines. Journal of Clinical Oncology. 23(16_suppl). 2012–2012. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evelyn Aranda Breakdown of academic impact, for papers by Houjie Liang Breakdown of academic impact, for papers by Daya Luo Breakdown of academic impact, for papers by Zarir E. Karanjawala Breakdown of academic impact, for papers by Keigo Araki Breakdown of academic impact, for papers by Sandeep Singh Breakdown of academic impact, for papers by Rajan Gogna Breakdown of academic impact, for papers by Melanie Spitzner Breakdown of academic impact, for papers by Robert S. Banh Breakdown of academic impact, for papers by Hannie Sietsma
Rankless by CCL
2026